Development and evaluation of co-formulated docetaxel and curcumin biodegradable nanoparticles for parenteral administration |
| |
Authors: | Harish Pawar Shrikant Rameshrao Wankhade Dharmendra K Yadav |
| |
Institution: | National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India |
| |
Abstract: | Context: Technology for development of biodegradable nanoparticles encapsulating combinations for enhanced efficacy.Objective: To develop docetaxel (DTX) and curcumin (CRM) co-encapsulated biodegradable nanoparticles for parenteral administration with potential for prolonged release and decreased toxicity.Materials and methods: Modified emulsion solvent-evaporation technique was employed in the preparation of the nanoparticles optimized by the face centered-central composite design (FC-CCD). The uptake potential was studied in MCF-7 cells, while the toxicity was evaluated by in vitro hemolysis test. In vivo pharmacokinetic was evaluated in male Wistar rats.Results and discussion: Co-encapsulated nanoparticles were developed of 219?nm size, 0.154 PDI, ?13.74?mV zeta potential and 67.02% entrapment efficiency. Efficient uptake was observed by the nanoparticles in MCF-7 cells with decreased toxicity in comparison with the commercial DTX intravenous injection, Taxotere®. The nanoparticles exhibited biphasic release with initial burst release followed by sustained release for 5 days. The nanoparticles displayed a 4.3-fold increase in AUC (391.10?±?32.94 versus 89.77?±?10.58?μg/ml min) in comparison to Taxotere® with a 6.2-fold increase in MRT (24.78?±?2.36 versus 3.58?±?0.21?h).Conclusion: The nanoparticles exhibited increased uptake, prolonged in vitro and in vivo release, with decreased toxicity thus exhibiting potential for enhanced efficacy. |
| |
Keywords: | Biodegradable nanoparticles co-encapsulation curcumin docetaxel face-centered design prolonged release |
|
|